A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Leap and Innate were clear winners on the stock market during the medical meeting, while Astrazeneca’s strong performance stands out among the large caps.
The company’s second foray with a PI3K inhibitor shows signs of additive activity, but investors punish it all the same.
A combination of Verastem’s small molecules shows promise in Kras-driven ovarian cancer, but shares fall on toxicity concerns.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.
For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.